Research Topics
Genomes and Genes | Alberto BallestreroSummaryAffiliation: University of Genoa Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyondA Ballestrero
Division of Semeiotics and Medical Methodology, Department of Internal Medicine, University of Genoa, Italy
Curr Cancer Drug Targets 12:316-28. 2012..Experimental topics and fields of ongoing research, such as targeting microRNAs (miRNAs) with novel anticancer drugs and epigenetics in CRC are also addressed...- Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cellsAlberto Ballestrero
Department of Internal Medicine, University of Genova, Genova, Italy
Clin Cancer Res 10:1463-70. 2004..evaluated whether chemoresistance associated with Bcl-2 and Bcl-x(L) overexpression would be overcome by activating the death receptor pathway by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in the Jurkat cell model.. - Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomasAlberto Ballestrero
Dipartimento di Medicina Interna, Universita di Genova, Viale Benedetto XV 6, 16132, Genova, Italy
Ann Hematol 87:49-55. 2008..In conclusion, a single injection of pegfilgrastim administered at day +5 post-transplantation shows comparable safety and efficacy profiles to daily injections of filgrastim and may be cost effective... 
Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancerA Ballestrero
Department of Internal Medicine, Universita di Genova, Viale Benedetto XV n 6, 16132 Genova, Italy
Br J Cancer 92:1948-52. 2005..These results suggest that MAM is more specific than maspin and that the possible interference of cytokines should be taken into account in interpreting molecular assays for detection of isolated tumour cells...
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipientsA Ballestrero
Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, Genoa, Italy
Int J Lab Hematol 32:387-91. 2010..3% of cases, and thus may be used to monitor the disease. This may be relevant when discussing both quality of life issues and the need for post-transplant monitoring with the patient...- Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capabilityAlberto Ballestrero
Dipartimento di Medicina Interna, Universita di Genova, Genova, Italy
Breast Cancer Res Treat 82:185-90. 2003..4-36.5). Four cycles of dose dense VNB and PTX showed a favorable toxicity profile, a relevant anti-tumor activity and a high peripheral blood progenitor cell mobilizing activity... - Ras-induced resistance to lapatinib is overcome by MEK inhibitionGabriele Zoppoli
Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy
Curr Cancer Drug Targets 10:168-75. 2010..Combining MEK inhibitors with lapatinib may help overcome this form of resistance and increase the efficacy of lapatinib in these tumors... - Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidasePaolo Spallarossa
Research Center of Cardiovascular Biology, Department of Cardiology, University of Genova, Viale Benedetto XV, 6 16132 Genova, Italy
Cardiovasc Res 69:736-45. 2006..CONCLUSIONS: Enhancement of MMP-2 and MMP-9 in cardiac myocytes in response to doxorubicin is mediated by the cooperation of ERK, JNK, and p38 kinase pathways, most of which are redox dependent... - Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cellsGabriele Zoppoli
Department of Internal Medicine, University of Genoa, Genoa, Italy
Exp Hematol 38:979-88. 2010..Here we have explored the interaction between APO866 and TRAIL in leukemia cell lines and in primary B-cell chronic lymphocytic leukemia cells... - The proteasome and its inhibitors in immune regulation and immune disordersAlessio Nencioni
Department of Internal Medicine, University of Genova, 16132 Genova, Italy
Crit Rev Immunol 26:487-98. 2006..The present review offers an overview of the mechanisms implicated in the immunomodulatory effects of proteasome inhibitors and discusses prospective future applications for these small molecules in immune and inflammatory diseases... - Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cellsMichele Cea
Department of Internal Medicine, University of Genoa, Genoa, Italy
PLoS ONE 6:e22739. 2011..In conclusion, NAD(+)-independent HDACs and sirtuins cooperate in leukemia cells to avoid apoptosis. Combining sirtuin with HDAC inhibitors results in synergistic antileukemic activity that could be therapeutically exploited... - Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myelomaAlberto Ballestrero
Department of Internal Medicine, University of Genova, Italy
Eur J Haematol 68:101-6. 2002..Our results are in agreement with the hypothesis that HDT results in an increased remission rate and in prolonged survival in newly diagnosed MM, but a cure is unlikely... - The use of dendritic cells in cancer immunotherapyAlessio Nencioni
Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy
Crit Rev Oncol Hematol 65:191-9. 2008..These issues are discussed here together with an overview of the DC-based antitumor immunotherapy studies... - A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemiaGabriella Cirmena
Department of Hematology, University of Genoa, V le Benedetto XV 6, 16132 Genoa, Italy
Cancer Genet Cytogenet 183:105-8. 2008..Previously, BCR-JAK2 rearrangement was observed in a single case with atypical chronic myelogenous leukemia (CML), but in that case the breakpoint in the BCR was different... - Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repressionAlessio Nencioni
Department of Internal Medicine, Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy
PLoS ONE 5:e9024. 2010..In conclusion, Grb7 upregulation is a potentially adverse consequence of HER2 signaling inhibition. Preventing Grb7 accumulation and/or its interaction with receptor tyrosine kinases may increase the benefit of HER2-targeting drugs... - Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activationAlessio Nencioni
Department of Internal Medicine, University of Genoa, Italy
Blood 108:551-8. 2006..These compounds could prove useful for tuning TLR signaling and for the treatment of inflammatory and immune-mediated disorders... - The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responsesInga Bauer
Department of Internal Medicine, Section of Biochemistry and Center of Excellence for Biomedical Research CEBR, University of Genoa, 16132 Genoa, Italy
J Biol Chem 287:40924-37. 2012..SIRT6 inhibition may help combat cancer-induced inflammation, angiogenesis, and metastasis... - Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicityAlessio Nencioni
Department of Internal Medicine, University of Genoa, Genoa, Italy
Clin Cancer Res 13:3933-41. 2007..Here, we have evaluated the effects of two HDAC inhibitors currently in clinical use, sodium valproate and MS-275, on human monocyte-derived DCs... - Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemiaAngelo M Carella
Department of Hematology, Azienda Ospedaliera Universitaria San Martino, L go R Benzi 10, 16132 Genova, Italy
Leuk Lymphoma 51:275-8. 2010..No low-risk patient carried KD mutation at diagnosis. In conclusion, KD mutations conferring high-level imatinib resistance are present in patients with de novo CML and in some of them lead to disease progression... - Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cellsAlessio Nencioni
Department of Internal Medicine, University of Genova, Genova, Italy
Eur J Immunol 36:681-9. 2006..In conclusion, induction of apoptosis in DC may represent a novel mechanism by which proteasome inhibitors affect the immune response at the antigen-presenting cell level... - Reliability and reproducibility of a RNA preamplification method for low-density array analysis from formalin-fixed paraffin-embedded breast cancer samplesPaola Ciotti
Department of Neuroscience, Ophthalmology, and Genetics, Section of Medical Genetics, University of Genova, Genova, Italy
Diagn Mol Pathol 18:112-8. 2009.... - Immunotherapy with dendritic cells for cancerAlberto Ballestrero
Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy
Adv Drug Deliv Rev 60:173-83. 2008..Here, we discuss these new insights together with an overview of the dendritic cell-based clinical studies carried out to date... - Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancerAlessio Nencioni
Department of Internal Medicine, University of Genova, Genoa, Italy
Cancer Gene Ther 10:209-14. 2003.... - Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAESantina Bruzzone
Department of Experimental Medicine, Section of Biochemistry, University of Genoa, Genoa, Italy
PLoS ONE 4:e7897. 2009..In conclusion, Nampt inhibitors (and possibly Sirt6 inhibitors) could be used to modulate T cell-mediated immune responses and thereby be beneficial in immune-mediated disorders... - Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trialR Murialdo
Department of Internal Medicine, S Martino Hospital, Viale Benedetto XV 6, 16132, Genoa, Italy
Cancer Chemother Pharmacol 68:1009-16. 2011..In the present phase II study, we investigated the activity of the same regimen as first-line treatment... - Rejuvenating sirtuins: the rise of a new family of cancer drug targetsSantina Bruzzone
Room 221, Department of Internal Medicine, University of Genoa, V le Benedetto XV 6, 16132 Genoa, Italy
Curr Pharm Des 19:614-23. 2013..Here, we review the biological rationale for the search of sirtuin inhibitors and activators for treating cancer and the experimental approaches to their identification... - Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitroPaolo Spallarossa
Laboratory of Cardiovascular Biology, Division of Cardiology, Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6 Genova 16132, Italy
J Mol Cell Cardiol 37:837-46. 2004..Our results suggest that carvedilol is potentially protective against doxorubicin cardiotoxicity by decreasing free radical release and apoptosis in cardiomyocytes... - Autologous peripheral blood stem cells (PBSC) in breast cancerFranco Patrone
Clinica di Medicina Interna I, DIMI, University of Genova and San Martino Hospital, Italy
Transfus Apher Sci 27:167-73. 2002 - Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental resultsN Castagnino
Department of Internal Medicine, University of Genoa, Genova, Italy
Curr Cancer Drug Targets 10:737-57. 2010.... - Reverse-transcriptase polymerase chain reaction of the maspin gene in the detection of bone marrow breast carcinoma cell contaminationA Ballestrero
Dipartimento di Medicina Interna, , Genova, Italy
Cancer 92:2030-5. 2001.... - Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11M Sessarego
Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, Italy
Haematologica 85:35-9. 2000..We studied two apparently Ph negative CML patients with unusual karyotypes both showing a typical b3a2 rearrangement... - High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and scheduleA Ballestrero
Dipartimento di Medicina Interna, , Genoa, Italy
Br J Cancer 76:797-804. 1997..It is concluded that, when adequately supported with PBPCs, NOV can be escalated up to 90 mg m(-2) with acceptable haematological toxicity. PBPCs can be safely reinfused as early as 96 h after NOV administration... - High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphomaA Ballestrero
Dipartimento di Medicina Interna, Universita di Genova, I 16132 Genova, Italy
Int J Oncol 17:1007-13. 2000..In A-AIPI group 1 the 2-year OS and FFS rates are both 91%... - Proteasome inhibitors as immunosuppressants: biological rationale and clinical experienceEva Moran
Department of Internal Medicine, University of Genoa, Genoa, Italy
Semin Hematol 49:270-6. 2012..Here, we discuss the biological rationale for the use of proteasome inhibitors as immunosuppressive agents and review the clinical experience with bortezomib in immune-mediated diseases... - HMGA2 overexpression in polycythemia vera with t(12;21)(q14;q22)Stefania Aliano
Laboratory of Cytogenetics, Department of Internal Medicine, University of Genoa, V le Benedetto XV 6, 16132 Genoa, Italy
Cancer Genet Cytogenet 177:115-9. 2007..Such overexpression may contribute to the pathogenesis of the disease, which otherwise of itself shows a favorable and stable course... - Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trialA Ballestrero
Department of Internal Medicine, Intensive Chemo-Immunotherapy Unit, University of Genoa, Genoa, Italy
Oncology 60:221-7. 2001..Although this regimen does not require stem cell harvesting and storage, it requires clinical support comparable to autotransplantation procedures and side effects are not so manageable to recommend its use outside specialized units... - Low Percentage of KRAS Mutations Revealed by Locked Nucleic Acid Polymerase Chain Reaction: Implications for Treatment of Metastatic Colorectal CancerMariella Dono
Molecular Diagnostic Division, Istituto di Ricovero e Cura a Carattere Scientitifico Azienda Ospedaliera Universitaria San Martino Istituto Nazionale per la Ricerca sul Cancro IRCCS AOU San Martino IST, Genova, Italy Department of Pathology, Istituto di Ricovero e Cura a Carattere Scientitifico Azienda Ospedaliera Universitaria San Martino Istituto Nazionale per la Ricerca sul Cancro IRCCS AOU San Martino IST, Genova, Italy
Mol Med 18:1519-26. 2013..Failure to respond to these biological treatments occurred even in the absence of mutations in other EGFR pathway components such as BRAF... - Germline mutations in the von Hippel-Lindau gene in Italian patientsPaola Ciotti
Department of Neuroscience, Ophthalmology, and Genetics Section of Medical Genetics, University of Genova and the Unit of Medical Genetics, Azienda Ospedaliera Universitaria San Martino of Genova, Viale Benedetto XV 6, Genova, Italy
Eur J Med Genet 52:311-4. 2009..In addition, an RQ-PCR protocol was validated in order to introduce it in the routine VHL laboratory diagnosis... - Gemcitabine and carboplatin treatment in advanced NSCLC: a retrospective evaluation including elderly patientsRoberto Murialdo
Department of Internal Medicine, S Martino Hospital, Genoa, Italy
Tumori 95:36-42. 2009..Carboplatin-containing regimens are sometimes preferred for patients with advanced non-small cell lung cancer... - The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast caM Setti
Department of Internal Medicine, University of Genoa, Viale Benedetto XV degrees 6, I 16132 Genoa, Italy
Cancer Immunol Immunother 48:287-96. 1999..The distinct pattern of the cytokine cascade induced by each factor, consistent with the different functional changes, seemed to account for the peculiarities of their immune modulations... - Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and moreM Cea
Department of Internal Medicine, University of Genoa, Genoa, Italy
J BUON 14:565-73. 2009..These issues are discussed here together with an overview on how patients treated with tyrosine kinase inhibitors should be monitored... - Proteasome inhibitors: antitumor effects and beyondA Nencioni
Department of Internal Medicine, University of Genova, Genova, Italy
Leukemia 21:30-6. 2007.... - Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosisAlessio Nencioni
Massachusetts Institute of Technology, Department of Biology, Center for Cancer Research, Cambridge, MA, USA
Blood 105:3255-62. 2005..Pharmacologic or genetic approaches targeting Mcl-1, including therapeutic RNAi, may increase the effectiveness of these compounds... - Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cellsAlessio Nencioni
Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
Clin Cancer Res 11:4259-65. 2005..Here, we evaluated whether Bcl-2 overexpression affects the cytotoxic activity of proteasome inhibitors taken alone or in association with conventional anticancer drugs or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)... - Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancerAngelo M Carella
Division of Haematology, Azienda Ospedaliera e Cliniche Universitarie San Martino, Largo R Benzi, 16132 Genoa, Italy
Lancet 366:318-20. 2005..No non-relapse-related deaths occurred during the first 100 days. Five patients (29%) were alive 90-2160 days (median 1320) after RICT. This two-step approach is feasible in patients with metastatic breast cancer...